Market capitalization | $650.83m |
Enterprise Value | $274.56m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.62 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-172.19m |
Free Cash Flow (TTM) Free Cash Flow | $-140.27m |
Cash position | $404.85m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a CARGO Therapeutics forecast:
10 Analysts have issued a CARGO Therapeutics forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -6.79 -6.79 |
-
|
|
EBITDA | -165 -165 |
-
|
EBIT (Operating Income) EBIT | -172 -172 |
-
|
Net Profit | -154 -154 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Mateo, CA.
Head office | United States |
CEO | Gina Chapman |
Founded | 2019 |
Website | cargo-tx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.